When atrophic vaginitis occurs in a woman with a prior hormone-sensitive malignancy — breast cancer or endometrial cancer — the clinical approach diverges from standard management. The history of malignancy shapes which interventions are appropriate and which carry unacceptable risk.
Non-hormonal options are primarily indicated in women wishing to avoid hormonal therapy or in high-risk individuals with a history of hormone-sensitive malignancy such as breast or endometrial cancer.
The primary clinical goal is relief of vaginal dryness. In this population, management focuses on non-hormonal vaginal preparations — the specific agents, their indications, and how to sequence them are detailed in the full protocol.
DOI: 10.3109/13697137.2010.522875
Non-hormonal options are primarily indicated in women wishing to avoid hormonal therapy or in high-risk individuals with a history of hormone-sensitive malignancy such as breast or endometrial cancer.
While systemic estrogen therapy is the most effective, this may be contraindicated, whereas non-hormonal vaginal moisturizer treatments and lubricants during intercourse can be used without limitation.
View source ↗